Our data on breast cancer patients indicates that high levels of MASTL protein correlates with tumor aggressiveness and predicts poor survival in two independent cohorts of ER + tumors, in line with the conclusions from a recent report using mRNA data [27]. This evidence concerns the gene ESR1 and neoplasm.